{"entity":{"id":"abbv-706","kind":"drug","name":"ABBV-706","aka":[],"tldr":"ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","summary":"ABBV-706 is an antibody-drug conjugate developed by AbbVie. The sponsor describes its target as SEZ6 (seizure-related homolog 6), which OnCo does not yet have a target page for. The sponsor states: ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07365241, plans to enrol 531 participants with primary completion expected 2030-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ABBV-706","url":"https://clinicaltrials.gov/search?intr=ABBV-706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07365241","nct07155174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/abbv-706/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}],"trial":[{"id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/"},{"id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/"}]}}